Study links TVT morphology to local immune response in dogs
Bottom line
A new paper in Animals examines why naturally occurring canine transmissible venereal tumors, or TVTs, can look and behave differently in dogs from Mexico. The researchers compared two field-observed forms: a steadier, pedunculated “strawberry-like” Type A tumor and a more progressive, multilobulated “cauliflower-like” Type B tumor. Their main finding was that Type A tumors showed a stronger, more balanced local immune response, while Type B tumors appeared to be associated with a weaker or less effective local response, helping explain why some lesions remain relatively steady and others keep advancing. The study adds histopathology and immune-cell data to a disease that remains common in some regions, including one Mexican community where prior work found a 5.15% prevalence. (mdpi.com)
Why it matters: For veterinary professionals, the paper is a reminder that TVT isn’t a uniform disease. Gross appearance may reflect meaningful biologic differences in the tumor microenvironment, not just cosmetic variation. That matters for differential diagnosis, case staging, prognosis discussions with pet parents, and treatment planning, especially in endemic settings where dogs may present late or with atypical lesions. TVT is usually diagnosed cytologically, can spread through coitus as well as sniffing, licking, or other contact, and is generally responsive to vincristine, but immune behavior helps determine whether tumors progress, stabilize, or regress. (mdpi.com)
What to watch: Watch for follow-up studies linking these histologic and immune patterns to treatment response, recurrence, or resistance in naturally occurring TVT cases. (mdpi.com)
A newly published Animals study offers a closer look at why some naturally occurring canine transmissible venereal tumors in Mexican dogs stay relatively stable while others continue to progress. The authors compared two commonly observed morphologic patterns in endemic areas: Type A, described as pedunculated and “strawberry-like,” and Type B, described as multilobulated and “cauliflower-like.” Their conclusion was that Type A tumors were associated with a stronger and more balanced local immune response than Type B tumors, suggesting that the tumor microenvironment may help shape how aggressively these lesions behave. (mdpi.com)
That question matters because TVT is one of the few naturally transmissible cancers in animals, and it remains enzootic in many tropical and subtropical regions even though it is now uncommon in much of North America and northern Europe. Transmission is classically venereal, but not exclusively so; tumor cells can also spread through sniffing, licking, scratching, biting, or other contact with abraded mucosa. In Mexico, prior field work from Cuajinicuilapa, Guerrero, found a 5.15% prevalence in 1,047 dogs, with clustering in certain areas and no lesions detected one year after treatment in the subset of dogs that were re-evaluated after vincristine-based care. (merckvetmanual.com)
The new study builds on that epidemiologic backdrop by focusing on pathology and local immunity rather than prevalence alone. According to the Animals article summary, the researchers found that the steadier Type A lesions had more robust local immune activity, while the progressive Type B lesions showed a comparatively less balanced response. That aligns with the broader CTVT literature, which has long framed the disease as a natural model of tumor immune evasion and immune-mediated regression. Recent comparative oncology commentary has described CTVT as a uniquely informative model for studying tumor-immune interactions, and earlier molecular work has identified distinct signatures associated with regression. (mdpi.com)
The findings also fit with what clinicians already know about the disease’s clinical variability. Merck Veterinary Manual notes that TVTs can appear as cauliflower-like, pedunculated, nodular, papillary, or multilobulated masses, and that although spontaneous regression can occur, disease is usually progressive unless treated. Cytology remains the practical diagnostic mainstay, while histology can be less definitive in some cases, especially at extragenital sites or when differentiating TVT from other round cell tumors. In that context, a paper tying morphology to local immune response may help explain why similarly diagnosed cases don’t always behave the same way in practice. (merckvetmanual.com)
I didn’t find a standalone press release or direct outside quote on this specific paper, but the broader expert view is consistent: host immunity is central to CTVT behavior. Merck’s review states that tumors may initially grow rapidly, particularly in immunosuppressed dogs, while comparative oncology literature describes CTVT as a natural model of immune evasion. Older and newer reviews alike point to a disease course that can include progressive, stationary, and regressive phases, with immune signaling and tumor-infiltrating lymphocytes influencing whether lesions keep growing or begin to resolve. That means the Mexican study is less a radical departure than a useful pathology-grounded extension of an established concept. (merckvetmanual.com)
Why it matters: For veterinarians, the practical takeaway is that visible tumor phenotype may carry biologic meaning. If future work confirms that certain morphologies track with distinct immune profiles, clinicians could eventually use gross appearance plus cytology and histopathology to better frame prognosis, monitor expected response, or identify cases that may need closer follow-up. This is especially relevant in regions with free-roaming dog populations, delayed presentation, or higher endemic burden, where TVT control depends on both effective treatment and population-level prevention. It also reinforces the importance of discussing transmission risk with pet parents, because TVT is not limited to mating and can involve extragenital sites after routine social contact. (mdpi.com)
Standard therapy is still unchanged: vincristine remains the treatment of choice in most cases, and remission is commonly achieved within several weekly doses. But studies like this one could eventually help clarify why some tumors respond faster, why some lesions appear more aggressive at presentation, and whether immune-targeted strategies might have a future role alongside conventional chemotherapy. Prior research has already explored regression-associated molecular signatures and even experimental immunotherapy approaches, though those remain outside routine practice. (merckvetmanual.com)
What to watch: The next step is validation, ideally in larger cohorts that connect morphology and local immune markers with outcomes such as vincristine response, time to remission, recurrence, and metastatic risk in naturally occurring cases. (mdpi.com)